Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 93, Issue 2, 1998, Pages 192-196

  Kagawa, Tatehiro ^a,b   Hosoi, Katsumi ^a   Takashimizu, Shinji ^a   Kawazoe, Kazuya ^a   Mochizuki, Kaori ^a   Wasada, Mitsuru ^a   Nagata, Naruhiko ^a   Uchiyama, Junzo ^a   Nakano, Atsushi ^a   Nishizaki, Yasuhiro ^a   Watanabe, Norihito ^a   Matsuzaki, Shohei ^a,b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHAN1 INTERFERON; LYMPHOBLAST INTERFERON; VIRUS RNA;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; EPISTAXIS; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TINNITUS;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 0032008393     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00192.x     Document Type: Article

References (26)

1. 1. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-6.
2. 2. DiBisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
3. 3. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France [see comments]. Hepatology 1991;13:393-7.
4. 4. Kagawa T, Morizane T, Saito H, et al. A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol 1993;17:91-6.
5. 5. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effect of dose and duration. Hepatology 1996;24:778-89.
6. 6. Hino K, Okuda M, Konishi T, et al. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-α therapy. Dig Dis Sci 1995;40:14-20.
7. 7. Orito E, Mizokami M, Suzuki K, et al. Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995;46:109-15.
8. 8. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-20.
9. 9. Kato N, Yokosuka O, Omata M. Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest 1990;86:1764-7.
10. 10. Kato N, Yokosuka O, Hosoda K, et al. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: Increase of the virus in advanced liver disease. Hepatology 1993;18: 16-20.
11. 11. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73: 673-9.
12. 12. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993;74:2385-90.
13. 13. Simmonds P, Alberti A, Alter H, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19: 1321-4.
14. 14. Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
15. 15. Yuki N, Hayashi N, Kasahara A, et al. Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. J Hepatol 1995;22:457-63.
16. 16. Lam NP, Neuman AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype I virus with interferon alfa. Hepatology 1997;26:226-31.
17. 17. Zeuzum S, Schmidt JM, Lee J-H, et al. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23: 366-71.
18. 18. Hakozaki Y, Shirahama T, Katou M, et al. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-9.
19. 19. Negro F, Baldi M, Mondardini A, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994;107:479-85.
20. 20. Jouet P, Thoraval FR, Dhumeaux D, et al. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hepatites Chroniques NANB/C. Gastroenterology 1994;106:686-90.
21. 21. Picciotto A, Callea F, Varagona G, et al. Lymphoblastoid interferon therapy in chronic hepatitis C: Biochemical, virological and histological evaluation of two different doses. Liver 1995;15:20-4.
22. 22. Marcellin P, Pouteau M, Martinot-Peignoux M, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-65.
23. 23. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995;22:700-6.
24. 24. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 1995;21:291-7.
25. 25. Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatology 1996;24:1034-40.
26. 26. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A non-B hepatitis. N Engl J Med 1995;332:1457-62.